Pharmaceutical

Grifols gears up for FDA approval of fibrinogen replacement therapy

Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.

Feb 14, 2024 - 18:00
Grifols gears up for FDA approval of fibrinogen replacement therapy
Grifols’ Phase III AdFIrst trial met its primary endpoint and the company plans to file for approval in Q4 2024.
Read the original article

Tags:

Previous Article

BMS signs $674m GenAI drug discovery deal with VantAI

Next Article

Sudo secures additional funds to advance TYK2 inhibitors to clinic

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Bezuclastinib by Cogent Biosciences for Systemic Mastocytosis: Likelihood of Approval

Bezuclastinib by Cogent Biosciences for Systemic Mastoc...

Nov 2, 2023

Nuvectis Pharma receives IND approval from FDA for NXP900

Nuvectis Pharma receives IND approval from FDA for NXP900

May 16, 2023

STAT+: Patients, doctors press FTC to beef up hospital merger scrutiny

STAT+: Patients, doctors press FTC to beef up hospital ...

Sep 18, 2023